GENERAL4 Sept 2026
Cipla partners with Qilu to license, supply Keytruda biosimilar in US
Drug maker Cipla has tied up with China's Qilu Pharmaceutical to sell a biosimilar version of Merck's cancer drug Keytruda in the United States. Cipla's US subsidiary Invagen will market the product, while Qilu will handle development and supply. The goal is to lower treatment costs and widen patient access to advanced cancer therapy. This tie-up supports Cipla's plan to strengthen its cancer-focused portfolio.
Key Statutory Highlights
- Cipla's US arm Invagen will market QL2107, a biosimilar to Merck's cancer drug Keytruda, in the United States.
- Under the deal, Qilu Pharmaceutical will handle development, regulatory registration and supply of the product.
- The partnership aims to improve access to advanced cancer therapies and cut treatment costs for patients.
Actionable Advice for Taxpayers / Founders:If you work in pharma or invest in it, keep an eye on US regulatory progress before assuming this partnership will bring revenues.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: